# Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection

> **NCT04333914** · PHASE2 · COMPLETED · sponsor: **Centre Leon Berard** · enrollment: 19 (actual)

## Conditions studied

- SARS-CoV-2 (COVID-19) Infection
- Advanced or Metastatic Hematological or Solid Tumor

## Interventions

- **DRUG:** Autophagy inhibitor (GNS651)
- **OTHER:** Standard of care
- **DRUG:** Avdoralimab
- **DRUG:** Monalizumab

## Key facts

- **NCT ID:** NCT04333914
- **Lead sponsor:** Centre Leon Berard
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2021-07-06
- **Final completion:** 2021-12-31
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04333914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04333914, "Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04333914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*